Hemophilia A Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Alnylam Pharmaceuticals, Sanofi Genzyme, Novo Nordisk, Catalyst Biosciences, BioMarin, Roche and Others 1
Hemophilia A Pipeline

Hemophilia A, also called factor VIII (8) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII (FVIII), a clotting protein. Hemophilia is inherited in an X-linked recessive manner. Hemophilia can vary in its severity, depending upon the particular type of mutation (genetic defect). The degree of symptoms depends upon the levels of the affected clotting factor.

DelveInsight’s, “Hemophilia A Pipeline Insight, 2021” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Some of Hemophilia A Companies are:

  • Alnylam Pharmaceuticals
  • Sanofi Genzyme
  • Novo Nordisk
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Chia Tai Tianqing Pharmaceutical Group
  • Staidson Beijing BioPharmaceuticals
  • Kymab
  • Poseida Therapeutics
  • Intellia Therapeutics
  • Regeneron Pharmaceuticals
  • Hoffmann-La Roche
  • Spark Therapeutics
  • BioMarin
  • Centessa Pharmaceuticals
  • Expression Therapeutics
  • Chugai Pharmaceutical
  • Pfizer
  • And Many Others


Request for free Sample Report: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight


DelveInsight’s Hemophilia A report covers around 45+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Some of Hemophilia A Therapies are:

  • Fitusiran
  • Concizumab
  • Marzeptacog alfa
  • Mim 8
  • DTX 201
  • TQG 203
  • STSP 0601
  • KY1049
  • P-VIII-101
  • CRISPR/Cas9 gene editing therapies
  • SPK-8011
  • BMN 270
  • SerpinPC
  • Ex-vivo hematopoietic stem cell (HSC) LV gene therapy
  • ACE910
  • PF-06741086
  • And Many Others


Request for free Sample Report: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight


Current Hemophilia A Treatment Scenario and Hemophilia A Emerging Therapies:

  • How many companies are developing Hemophilia A drugs?
  • How many Hemophilia A drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemophilia A?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hemophilia A therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hemophilia A and their status?
  • What are the key designations that have been granted to the emerging drugs?


Request for free Sample Report: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight


Table of Contents:


Executive Summary

Hemophilia A: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Hemophilia A – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Hemophilia A Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Fitusiran: Alnylam Pharmaceuticals/Sanofi Genzyme

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Drug name: Company name

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

• Comparative Analysis

DTX 201: Dimension Therapeutics

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

• Comparative Analysis

KY1049: Kymab

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Hemophilia A Key Companies

Hemophilia A Key Products

Hemophilia A- Unmet Needs

Hemophilia A- Market Drivers and Barriers

Hemophilia A- Future Perspectives and Conclusion

Hemophilia A Analyst Views

Hemophilia A Key Companies


Request for Detailed TOC: https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insig


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight